foslevodopa/foscarbidopa vs Levodopa/carbidopa (ND0612)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

foslevodopa/foscarbidopa · Vyalev

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT04380142 · Phase 3 · completed

The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).

Reported efficacy

Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)

Result source: NCT04380142

Levodopa/carbidopa (ND0612) · Onerji

Marketed by NeuroDerm Ltd.

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02577523 · Phase 2 · completed

Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.

Reported efficacy

Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)

Result source: NCT02577523

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfoslevodopa/​foscarbidopaLevodopa/​carbidopa (ND0612)
OFF time, change-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505
ON time without troublesome dyskinesia, change2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142—Trial running · NCT04006210
UPDRS Part III, change—Not posted · NCT04379050—Trial running · NCT04006210
MDS-UPDRS Part II, change-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142—Trial running · NCT04006210

OFF time, change

foslevodopa/​foscarbidopa
-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa/​carbidopa (ND0612)
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505

ON time without troublesome dyskinesia, change

foslevodopa/​foscarbidopa
2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

UPDRS Part III, change

foslevodopa/​foscarbidopa
—Not posted · NCT04379050
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

MDS-UPDRS Part II, change

foslevodopa/​foscarbidopa
-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. foslevodopa/foscarbidopa: 5 of 5 rows · Levodopa/carbidopa (ND0612): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfoslevodopa/​foscarbidopa
Rows use multiple source trials
Levodopa/​carbidopa (ND0612)
Rows use multiple source trials
OFF Time
absolute change · hours
No placebo or comparator arm
-3.51 hours @ 52wka,b,c,d,e
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more doses
-3.59 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.43 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.8 hours @ 4wk24-hr Infusiona,b,c,d,e
NCT02577523 · Phase 2
show 1 more dose
-1.3 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
Dropout rate
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
42.5%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
35.9%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
0%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
22.1%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
17.6%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
—Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
8.1%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
25.8%ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.4%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24.4%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.5%24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
10.5%14-hr Infusion
NCT02577523 · Phase 2
5.3%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
infusion site erythema 27%
infusion site pain 25.7%
infusion site cellulitis 17.6%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
infusion site erythema 52%
infusion site nodule 28.7%
infusion site oedema 19.3%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
high dose
infusion site erythema 55.8%
infusion site nodule 30.1%
infusion site oedema 24.8%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
low dose
infusion site erythema 48.9%
infusion site nodule 27.5%
infusion site cellulitis 19.1%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24-hr Infusionf
infusion site nodule 57.9%
infusion site erythema 26.3%
infusion site bruising 21.1%
NCT02577523 · Phase 2
show 4 more results
14-hr Infusion
infusion site nodule 36.8%
infusion site bruising 15.8%
infusion site haemorrhage 15.8%
NCT02577523 · Phase 2
fatigue 10.5% (placebo 0%)
headache 10.5% (placebo 9.1%)
abdominal pain lower 5.3% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
blood creatinine abnormal 12.5% (placebo 0%)
dental caries 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 52 weeks versus 4 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

foslevodopa/foscarbidopa

On" Time Without Troublesome Dyskinesia 2.72 vs 0.97 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.65 vs -1.06 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Early Morning "Off 17% (n=47) vs 63.3% (n=60) LD/CD @ 12wk
responder rate · % of participants
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
ON Time Without Dyskinesia 3.13 vs 1.32 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDSS-2 Total -7.92 vs -2.52 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDQ-39 Summary Index -6.38 vs -2.28 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
EQ-5D-5L Summary Index 0.051 vs 0.002 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Daily on Time With Troublesome Dyskinesia 0 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
0.11 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.05 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.56 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.23 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.41 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.6 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.38 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.61 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.45 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.49 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.17 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.35 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.64 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.17 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
1.74 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.99 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.6 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.81 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.72 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.93 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.92 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.65 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.79 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.74 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.69 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.71 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.43 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.77 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part I -2.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.4 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.8 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.4 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.3 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.8 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.2 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.4 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.5 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.9 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.2 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.3 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.9 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-4.5 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.2 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III -0.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-0.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.8 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.8 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.1 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.9 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.9 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.2 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.5 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.4 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.9 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.6 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.8 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.3 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.1 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.8 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.7 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.7 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

+ 4 further endpoints in the CSV export.

Levodopa/carbidopa (ND0612)

Good ON" Time 3.7 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
2.8 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 3 Motor -19.1 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-10.7 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 2 ADL -2.9 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.9 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
CGI-I 52.6% (n=19) @ 0.43wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 10 Participants as posted
show 1 more result
47.4% (n=19) @ 0.43wk*14-hr Infusion
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 9 Participants as posted
CGI-I 73.7% (n=19) @ 4wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 14 Participants as posted
show 1 more result
68.4% (n=19) @ 4wk*14-hr Infusion
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 13 Participants as posted
PDSS-2 -4.1 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-0.8 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
PDQ-39 Summary Index -7.5 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-3.7 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Total -11.7 vs -9.3 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDSS -17.1 vs -0.5 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDQ-39 -6.6 vs -1.8 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
CGIC 89.5% (n=19) vs 36.4% (n=11) placebo @ 2wk
event count · % of participants
Improved
NCT01883505 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa/carbidopa (ND0612)'s landscape